ABSTRACTBackground Peroxisome proliferator‐activated receptors (PPAR) mediate inflammatory processes and alter cardiac function. However, it is not clear whether inflammatory cytokines or PPAR ligands regulate PPARs in the cardiomyocytes to modulate cardiac functions. We investigated the effects of tumour necrosis factor‐alpha (TNF‐α) and PPAR ligands on the expression of PPARs in HL‐1 cardiomyocytes.Materials and methods HL‐1 cardiomyocytes were incubated with and without TNF‐α (1, 10, 25 and 50 ng mL−1) or PPAR ligands (rosiglitazone, pioglitazone and fenofibrate) at concentrations of 0·1, 1 and 10 µm for 24 h. The cells also received SN‐50 (NF‐κB inhibitor, 50 µg mL−1), ascorbic acid (100 µm) and coenzyme Q10 (10 µm) alone or combined with TNF‐α.Results Using reverse transcriptase–polymerase chain reaction and Western blot, we found that incubation of TNF‐α (50 ng mL−1) for 24 h decreased PPAR‐α, but increased PPAR‐γ without altering PPAR‐δ. These effects were not changed by co‐administration of SN‐50. However, co‐administration of ascorbic acid prevented the effect of TNF‐α both on PPAR‐α and PPAR‐γ. Coenzyme Q10 partially attenuated the effect of TNF‐α on PPAR‐γ but did not alter its effect on PPAR‐α. The administration of rosiglitazone (10 µm) and pioglitazone (10 µm) for 24 h increased PPAR‐γ mRNA, but did not alter PPAR‐α or PPAR‐δ. Moreover, fenofibrate (0·1, 1 and 10 µm) increased PPAR‐γ without any effects on PPAR‐α or PPAR‐δ.Conclusions Oxidative stress causes the regulations of PPAR‐α and PPAR‐γ in the TNF‐α‐treated cardiomyocytes. The up‐regulation of PPAR‐γ by PPAR ligands may contribute to their anti‐inflammation effects.

01 Sep 2008·Journal of NeurochemistryQ2 · MEDICINE

NFκB in the mechanism of ammonia‐induced astrocyte swelling in culture

Q2 · MEDICINE

Article

Author: Michael D Norenberg ; Arumugam R Jayakumar ; Mitsuaki Moriyama ; Kiran S Panickar ; Anne P Sinke ; Pichili V B Reddy

AbstractAstrocyte swelling and brain edema are major neuropathological findings in the acute form of hepatic encephalopathy (fulminant hepatic failure), and substantial evidence supports the view that elevated brain ammonia level is an important etiological factor in this condition. Although the mechanism by which ammonia brings about astrocyte swelling remains to be determined, oxidative/nitrosative stress and mitogen‐activated protein kinases (MAPKs) have been considered as important elements in this process. One factor known to be activated by both oxidative stress and MAPKs is nuclear factor κB (NFκB), a transcription factor that activates many genes, including inducible nitric oxide synthase (iNOS). As the product of iNOS, nitric oxide (NO), is known to cause astrocyte swelling, we examined the potential involvement of NFκB in ammonia‐induced astrocyte swelling. Western blot analysis of cultured astrocytes showed a significant increase in NFκB nuclear translocation (a measure of NFκB activation) from 12 h to 2 days after treatment with NH4Cl (5 mM). Cultures treated with anti‐oxidants, including superoxide dismutase, catalase, and vitamin E as well as the MAPKs inhibitors, SB239063 (an inhibitor of p38‐MAPK) and SP600125 (an inhibitor of c‐Jun N‐terminal kinase), significantly diminished NFκB activation by ammonia, supporting a role of oxidative stress and MAPKs in NFκB activation. The activation of NFκB was associated with increased iNOS protein expression and NO generation, and these changes were blocked by BAY 11–7082, an inhibitor of NFκB. Additionally, ammonia‐induced astrocyte swelling was inhibited by the NFκB inhibitors, BAY 11–7082 and SN‐50, thereby implicating NFκB in the mechanism of astrocyte swelling. Our studies indicate that cultured astrocytes exposed to ammonia display NFκB activation, which is likely to be a consequence of oxidative stress and activation of MAPKs. NFκB activation appears to contribute to the mechanism of ammonia‐induced astrocyte swelling, apparently through its up‐regulation of iNOS protein expression and the subsequent generation of NO.

01 Jul 2007·The FEBS JournalQ3 · BIOLOGY

Staphylococcal enterotoxin C1‐induced pyrogenic cytokine production in human peripheral blood mononuclear cells is mediated by NADPH oxidase and nuclear factor‐kappa B

Q3 · BIOLOGY

Article

Author: Yeh, Hsiao-Chun ; Lee, Jenq-Chang ; Won, Shen-Jeu ; Lee, Meng-Chou ; Cheng, Chun-Chun ; Su, Chun-Li ; Lin, Mao-Tsun

The staphylococcal enterotoxins produced by Staphylococcus aureus are associated with pyrogenic response in humans and primates. This study investigates the role of NADPH oxidase and nuclear factor‐kappa B (NF‐κB) on enterotoxin staphylococcal enterotoxin C1 (SEC1)‐induced pyrogenic cytokine production in human peripheral blood mononuclear cells (PBMC). The results indicate that the febrile response to the supernatant fluids of SEC1‐stimulated PBMC in rabbits was in parallel with the levels of interleukin‐1β and interleukin‐6 in the supernatants. The release of interleukin‐1β and interleukin‐6, nuclear translocation of NF‐κB and its DNA binding activity in the SEC1‐stimulated PBMC were time‐dependent and were completely eliminated by pyrrolidine dithiocarbamate or SN‐50 (NF‐κB inhibitors). The release of reactive oxygen species in the supernatants and translocation of the NADPH oxidase p47phox subunit to the plasma membrane of SEC1‐stimulated PBMC were time‐dependent. Administration of apocynin (NADPH oxidase inhibitor) attenuated the febrile response to the supernatants in rabbits and decreased the translocation of NADPH oxidase p47phox subunit and NF‐κB activity in the SEC1‐stimulated PBMC, and suppressed reactive oxygen species and pyrogenic cytokine production in the supernatants. Taken together, SEC1 may act through an NADPH oxidase mechanism to release reactive oxygen species, which activate NF‐κB in PBMC to stimulate the synthesis of pyrogenic cytokines that trigger a fever response in rabbits.

100 Deals associated with Agalsidase Beta(Nipro ES Pharma)

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Lactose Intolerance	Japan	Nipro ES Pharma KK	25 Sep 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis